Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in Southern Africa has been steadily growing in recent years, driven by various factors such as increasing prevalence of autoimmune diseases, rising geriatric population, and growing healthcare expenditure in the region.
Customer preferences: Patients in Southern Africa have shown a preference for biologic immunosuppressants over traditional drugs due to their higher efficacy and lower risk of adverse effects. However, the high cost of biologics remains a major barrier for many patients, leading to a growing demand for more affordable generic alternatives.
Trends in the market: South Africa accounts for the largest share of the immunosuppressants market in the region, with a growing demand for drugs to treat autoimmune diseases such as rheumatoid arthritis and lupus. The market for immunosuppressants in other countries such as Zimbabwe, Zambia, and Botswana is also expected to grow in the coming years, driven by increasing awareness and availability of these drugs.
Local special circumstances: The Southern African region is characterized by a high burden of infectious diseases such as HIV/AIDS and tuberculosis, which can lead to the development of autoimmune diseases that require immunosuppressive therapy. Additionally, the region has a large population of indigenous people who have a higher risk of developing autoimmune diseases such as systemic lupus erythematosus (SLE).
Underlying macroeconomic factors: The healthcare sector in Southern Africa is undergoing rapid transformation, with increasing investment in healthcare infrastructure, rising healthcare expenditure, and growing private sector participation. This is expected to drive the demand for immunosuppressants in the region, as more patients gain access to healthcare services and drugs.In conclusion, the immunosuppressants market in Southern Africa is expected to continue growing in the coming years, driven by increasing prevalence of autoimmune diseases, rising healthcare expenditure, and growing demand for more affordable drugs. However, challenges such as high cost of biologics and the burden of infectious diseases will need to be addressed in order to ensure sustained growth in the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
